Orforglipron — Benefits, Dosage & Where to Buy
Research Overview
Orforglipron is a first-in-class oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (Rybelsus), which is a peptide requiring specific fasting conditions for absorption, orforglipron is a small molecule with superior oral bioavailability that can be taken without food restrictions. In phase 2 trials, orforglipron produced up to 14.7% body weight loss at 36 weeks in people with obesity, comparable to injectable GLP-1 agonists. The compound also showed significant HbA1c reductions in type 2 diabetes patients. As an oral daily pill rather than weekly injection, orforglipron could dramatically expand the GLP-1 market by removing the injection barrier. Phase 3 trials (ACHIEVE program) are underway.
Key Research Findings
- •First oral non-peptide GLP-1 receptor agonist
- •Up to 14.7% weight loss in 36-week phase 2 trial
- •Daily oral pill with no food restrictions
- •Significant HbA1c reduction in type 2 diabetes
- •Could expand GLP-1 market by eliminating injection barrier
- •Phase 3 ACHIEVE trials ongoing
Published Research (2 studies)
- [1]
- [2]
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (2 products from 2 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Swiss Chems | $198.95 $33.16/mg 6mg capsule | In Stock |
| Simple Peptide | $239.00 $39.83/mg 6mg capsule | In Stock |